Literature DB >> 24526323

Tamper-resistant opioid formulations in the treatment of acute pain.

Steven D Passik1.   

Abstract

INTRODUCTION: Pain-including acute or persistent acute pain-is a common condition that is increasingly being treated with opioids in the United States. The acute pain treatment setting may represent a key target for addressing the growing epidemic of prescription drug abuse occurring hand in hand with the rise in opioid prescribing. Balancing the needs of pain treatment with abuse prevention can be challenging for clinicians.
METHODS: This article identified efforts to balance opioid abuse risks with opioid availability through the extensive experience of the author in this field. In addition, PubMed literature searches using terms such as "prescription opioid abuse", "abuse-deterrent opioids", and "tamper-resistant opioids"; and inspection of the bibliographies of relevant articles were used to identify relevant sources.
RESULTS: These multifaceted efforts have included: improving assessment of patient risk for drug misuse, abuse, or diversion; funding of and encouraging referral to addiction treatment programs; access to and widespread use of prescription monitoring programs (PMPs); public knowledge of prescription opioid abuse; proper storage of opioid medications; and development of new formulations designed to resist tampering and deter abuse. This review discusses the problem of prescription opioid abuse and strategies to minimize risk within the context of acute pain treatment, and explores the potential role of tamper-resistant opioid formulations and other abuse deterrence strategies in the area of acute or persistent acute pain management.
CONCLUSION: In order to stem the tide of prescription opioid abuse and preserve the availability of opioids as a much needed analgesic option, a multifaceted approach that includes tamper-resistant opioid formulations-for chronic or acute pain-along with strategies such as improved patient risk assessment, funding for and referral to addiction treatment programs, greater use of PMPs, and raised awareness of prescription opioid abuse is needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24526323     DOI: 10.1007/s12325-014-0099-7

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  4 in total

Review 1.  [Misuse of opioid analgesics. An internet analysis].

Authors:  R Krüger; W Meißner; A Zimmer
Journal:  Schmerz       Date:  2014-10       Impact factor: 1.107

2.  Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.

Authors:  Arnold J Weil; Elizabeth T Masters; Alexandra I Barsdorf; Almasa Bass; Glenn Pixton; Jacquelyn G Wilson; Gernot Wolfram
Journal:  Health Qual Life Outcomes       Date:  2017-10-17       Impact factor: 3.186

3.  The damage done by the war on opioids: the pendulum has swung too far.

Authors:  Timothy J Atkinson; Michael E Schatman; Jeffrey Fudin
Journal:  J Pain Res       Date:  2014-05-12       Impact factor: 3.133

4.  Polyglycerol-opioid conjugate produces analgesia devoid of side effects.

Authors:  Sara González-Rodríguez; Mohiuddin A Quadir; Shilpi Gupta; Karolina A Walker; Xuejiao Zhang; Viola Spahn; Dominika Labuz; Antonio Rodriguez-Gaztelumendi; Martin Schmelz; Jan Joseph; Maria K Parr; Halina Machelska; Rainer Haag; Christoph Stein
Journal:  Elife       Date:  2017-07-04       Impact factor: 8.140

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.